welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
Sedation During Muscle Biopsy in Patients With Duchenne Muscular Dystrophy
study id #: NCT01645098
condition: Duchenne Muscular Dystrophy
This is an interventional study on Duchenne muscular dystrophy patients who will be receiving sedation for a muscle biopsy as part of another study.
intervention: Ketamine, Dexmedetomidine
mechanism of action: Sedation during moderately painful procedures
last updated: November 22, 2018
start date: August 2011
estimated completion: June 2013
phase of development: N/A
size / enrollment: 53
- Time to Sedation Score of 3-4 [ Time Frame: Immediately prior to incision ]
The depth of sedation was judged using the University of Michigan Sedation Scale (UMSS). The score ranges from zero, awake and alert, to four, unarousable. A score of three, deeply sedated, or more was considered to be an appropriate level of sedation for the procedure.
- Heart Rate Change After Dexmedetomidine Loading Dose [ Time Frame: Baseline to immediately post dexmedetomidine infusion. ]
Difference in heart rate from baseline to immediately following infusion of dexmedetomidine loading dose.
- Mean Arterial Pressure (MAP) Change After Dexmedetomidine Loading Dose [ Time Frame: Baseline to immediately post dexmedetomidine infusion. ]
Change in MAP from baseline measurement to immediately post dexmedetomidine infusion measured via blood pressure cuff.
- Oxygen Saturation Change After Dexmedetomidine Loading Dose [ Time Frame: Baseline to immediately post dexmedetomidine infusion. ]
Change in oxygen saturation from baseline measurement to immediately post dexmedetomidine infusion.
- EtCO2 Change After Dexmedetomidine Loading Dose [ Time Frame: Baseline to immediately post dexmedetomidine infusion. ]
Change in end-tidal carbon dioxide from baseline measurement to immediately post dexmedetomidine infusion.
Patients undergoing a muscle biopsy for IRB11-00203.
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular DystrophyThe primary objective of this study is t...
Analysis of a Virtual Reality Task in Patients With Duchenne Muscular DystrophyThe task consists in reach as much bubbl...
Allogeneic Human Umbilical Cord Mesenchymal Stem Cells for a Single Male Patient With Duchenne Muscular Dystrophy (D...This research study is designed to evalu...
Effect of Modulating the nNOS System on Cardiac, Muscular and Cognitive Function in Becker Muscular Dystrophy Patien...This study is done to evaluate whether t...
Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular DystrophiesThe study will include 120 participants ...
PhaseOut DMD: a Phase 2, proof of concept, clinical study of utrophin modulation with ezutromidThis study investigates the hypothesis t...
Study of Ataluren in >=2 to <5 Year-Old Males With Duchenne Muscular DystrophyThis is a Phase 2, multiple-dose, open-l...
DMD clinical therapies II: P.135 DMD-HUB: expanding clinical trial capacity for Duchenne muscular dystrophy, 1 year ...The need to increase capacity for Duchen...
Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double...Background: Duchenne muscular dystrophy...
Rare diseases require unique approaches in clinical trial designThere are 7,000 known rare diseases and ...
Sarepta Therapeutics to Provide Update on Duchenne Muscular Dystrophy Gene Therapy ProgramSarepta Therapeutics, Inc., the leader i...